关于纳米粒子狂热度与生物分布之间的相关性不确定性
Oliver Zimmer1, Achim Goepferich1
1Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Bavaria 93053, Germany.
概括
使用连接体功能化纳米颗粒的向药物递送面临挑战,原因是对纳米颗粒-细胞相互作用的理解不足. 本综述探讨了纳米粒子热情及其对生物分布的影响,以改善有针对性的交付.
科学领域:
- 药品制造 药品制造 药品制造
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
背景情况:
- 向药物输送旨在通过将药物集中在特定地点来提高治疗效果.
- 带功能化纳米粒子是实现有针对性的交付的关键策略.
- 在预测纳米粒子行为和生物系统中的积累方面仍然存在挑战.
研究的目的:
- 引入热情的概念作为纳米粒子-细胞膜相互作用的衡量标准.
- 审查纳米粒子和膜特性影响激情.
- 分析纳米粒子热情与包括生物分布在内的有针对性的交付成功之间的相关性.
主要方法:
- 文献综述侧重于纳米粒子-细胞相互作用和多价值体结合.
- 在纳米颗粒传递的背景下,对欲的概念性介绍.
- 分析现有关于欲在生物分布中的作用的数据.
主要成果:
- 性,多价值结合强度的衡量标准,对于纳米粒子附着在细胞中至关重要.
- 纳米粒子和细胞膜的特性显著影响激情.
- 热情与成功的有针对性的交付,特别是生物分销之间的准确相关性需要进一步调查.
结论:
- 了解纳米粒子热情对于优化向药物递送系统至关重要.
- 需要进一步的研究来阐明贪和体内生物分布模式之间的复杂关系.
- 改善欲的预测和控制可以提高纳米药物的疗效.
相关概念视频
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
171
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
171
Drug Distribution: Plasma Protein Binding
5.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.6K
Volume of Distribution
176
The apparent volume of distribution (Vd) is a crucial pharmacokinetic parameter representing the hypothetical body fluid volume into which a drug disperses. It is calculated based on the total amount of drug in the body (estimated from the administered dose and bioavailability) divided by the plasma drug concentration. The total amount of drug in the body does not directly refer to the dose given but is derived by accounting for absorption, distribution, metabolism, and excretion processes.
176
Physiological Pharmacokinetic Models: Assumption with Protein Binding
44
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
44
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K


